News | Contrast Media | October 14, 2022

Enables GE Healthcare to secure increasing supply of iodine, a key ingredient for contrast media products used in X-Ray and Computed Tomography (CT) imaging procedures

Iodine prills – produced by SQM (Photo: Business Wire)

Iodine prills – produced by SQM (Photo: Business Wire) 

 


October 14, 2022 —  GE Healthcare’s Pharmaceutical Diagnostics business has announced a long-term agreement with Chile-based mining company, Sociedad Quimica y Minera de Chile S.A. (SQM), to secure its supply of iodine, a key ingredient for contrast media products used in X-Ray and Computed Tomography (CT) procedures globally. The agreement will see SQM increase supply of iodine raw material year-on-year and is part of GE Healthcare’s broader commitment and investment plan to enable the production of 30 million more patient doses of iodinated contrast media annually by 2025. 

The growing global prevalence of chronic disorders has driven significant growth in CT procedures, leading to increased global demand for iodinated contrast media, used to enhance visualization of organs, blood vessels and tissues across clinical care pathways. GE Healthcare is also investing in production capacity to help meet this growing demand, including a new $30 million manufacturing line at its Cork, Ireland, contrast media production facility, which opens this week. 

Kevin O’Neill, President and CEO, GE Healthcare Pharmaceutical Diagnostics, said: “We expect global demand for iodinated contrast media to double in the next 10 years. As an industry leader, we understand our responsibility to help meet this growing demand from customers and patients by investing in production capacity and securing higher volumes of iodine raw material. As one of the largest consumers of iodine globally we value our longstanding relationship with SQM, an important partner for us.” 

Pablo Altimiras, Executive Vice President of Iodine and Nitrates, SQM, said: “We’re pleased to continue our relationship with GE Healthcare – a key customer for us for more than 40 years. As one of the largest producers of iodine worldwide with approximately 24 percent of our production used for X-ray contrast media, we are committed to the iodine industry and will continue to improve quality and increase capacity to ensure the reliability of supply, which is essential to so many sectors, including healthcare.” 

GE Healthcare Pharmaceutical Diagnostics develops and manufactures imaging agents used to support over 100 million procedures per year, equivalent to three patient procedures every second. All stages of its contrast media manufacturing, from development of API to finished product, are managed entirely by GE Healthcare, adhering to current Good Manufacturing Practices (cGMP). With over 4000 employees globally and seven manufacturing sites, the business also develops and supplies radiopharmaceuticals used to support diagnosis, monitoring and treatment selection across Neurology, Cardiology and Oncology clinical pathways. 

 

For more information: www.gehealthcare.com 

Find more RSNA22 coverage here  

Related Content of MRI Gadolinium Concerns 

Contrast Media Supply Shortage: How and What Now? 

AJR Publishes Best Practices for Iodinated Contrast Media Shortage 

Voluntary Dismissal of Chuck Norris Gadolinium Case Involving Bracco 

VIDEO: How Serious is MRI Gadolinium Retention in the Brain and Body? An interview with Max Wintermark, M.D. 

VIDEO “Big Concerns Remain for MRI Gadolinium Contrast Safety at RSNA 2017,” An interview with Emanuel Kanal, M.D. 

Radiology Has Failed to Properly Assess or Track MRI Gadolinium Contrast Safety 

Recent Developments in Contrast Media 

FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents 

European Medicines Agency Issues Update on Gadolinium Contrast Agents 

 


Related Content

News | Artificial Intelligence

February 29, 2024 — AIxSCAN, Inc., a Sunnyvale, CA-based developer of a next generation artificial intelligence (AI) ...

Time February 29, 2024
arrow
News | Artificial Intelligence

February 27, 2024 — Median Technologies announced that the Company will be participating and speaking at the premier ...

Time February 27, 2024
arrow
News | Artificial Intelligence

February 27, 2024 — As artificial intelligence (AI) is increasingly used in radiology, researchers caution that it’s ...

Time February 27, 2024
arrow
News | X-Ray

February 26, 2024 — AIxSCAN, Inc. began clinical trials in late 2023. The AIxSCAN, Inc. team is very pleased with the ...

Time February 26, 2024
arrow
News | Radiology Imaging

February 23, 2024 — Can dual-energy tomosynthesis be performed portably? This is one of the topics to be discussed by KA ...

Time February 23, 2024
arrow
News | Computed Tomography (CT)

February 20, 2024 — Ultrahigh-spatial-resolution photon-counting detector CT improved assessment of coronary artery ...

Time February 20, 2024
arrow
News | Breast Imaging

February 20, 2024 — Annual breast cancer screening beginning at age 40 and continuing to at least age 79 results in the ...

Time February 20, 2024
arrow
Sponsored Content | Videos | Enterprise Imaging

Clinicians and referring physicians need fast, secure access to both patient data and their diagnostic or viewing tool ...

Time February 15, 2024
arrow
Sponsored Content | Videos | Digital Radiography (DR)

Agfa Radiology Solutions is committed to enhancing clinical outcomes and operational efficiency, underscoring its ...

Time February 12, 2024
arrow
News | Breast Imaging

February 9, 2024 — An innovative breast imaging technique provides high sensitivity for detecting cancer while ...

Time February 09, 2024
arrow
Subscribe Now